CTI Biopharma | CTIC - Current Liabilities


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

CTI Biopharma

CTI Biopharma reported $68.23M in Current Liabilities for its fiscal quarter ending in March of 2023.


Current Liabilities Change
Baxter International BAX:US USD 4.76B 15M
CTI Biopharma CTIC:US USD 68.23M 12.91M
Eli Lilly LLY:US USD 16.01B 1.13B
Geron GERN:US USD 43.91M 32.78M
Incyte Corp INCY:US USD 1.01B 150.97M
Mirati Therapeutics MRTX:US USD 124.6M 34.85M
Northwest Biotherapeutics NWBO:US USD 44.71M 81.3M
Novartis NOVN:VX USD 30.55B 1.89B
Novartis NVS:US USD 30.55B 1.89B
Plus Therapeutics, Inc. CYTX:US USD 12.8M 944K
Seattle Genetics SGEN:US USD 713.23M 105.18M